Tools
Tools
Maksymowych, Walter P., Thom, Howard, Mørup, Michael F., Taieb, Vanessa, Willems, Damon, Lyris, Nikos and Gaffney, Karl 
ORCID: https://orcid.org/0000-0002-7863-9176
(2024)
Matching-adjusted indirect comparison of the 52-week efficacy of bimekizumab versus secukinumab and ixekizumab for the treatment of radiographic axial spondyloarthritis.
Rheumatology and Therapy, 11 (4).
pp. 1023-1041.
ISSN 2198-6576
Preview |
PDF (Maksymowych_etal_2024_RheumatologyAndTherapy)
- Published Version
Available under License Creative Commons Attribution Non-commercial. Download (1MB) | Preview |
Abstract
Introduction: A previous network meta-analysis established 16-week relative efficacy with bimekizumab, an inhibitor of interleukin (IL)-17F in addition to IL-17A, versus other treatments for patients with radiographic axial spondyloarthritis (r-axSpA; i.e., ankylosing spondylitis), including the IL-17A inhibitors secukinumab and ixekizumab. This matching-adjusted indirect comparison (MAIC) assessed 52-week relative efficacy of bimekizumab versus secukinumab and ixekizumab. Methods: Individual patient data from BE MOBILE 2 (bimekizumab 160 mg; N = 220) were matched to pooled summary data from MEASURE 1/2/3/4 (secukinumab 150 mg), MEASURE 3 (secukinumab 300 mg; escalated dose for inadequate responders), COAST-V (ixekizumab) and COAST-V/-W (ixekizumab). BE MOBILE 2 patients were reweighted using propensity score weights based on age, sex, ethnicity, tumor necrosis factor inhibitor (TNFi) exposure, weight, baseline ASDAS and BASFI (secukinumab) and baseline BASDAI (ixekizumab), and 52-week efficacy outcomes from the trial recalculated. Odds ratios (OR) or mean difference for unanchored comparisons are reported with 95% confidence intervals (CI). Results: At week 52, MAIC demonstrated that patients may have higher likelihood of improvement in key efficacy outcomes with bimekizumab versus secukinumab 150 mg (e.g., ASAS40: [OR (95% CI): 1.48 (1.05, 2.10); p = 0.026]; effective sample size [ESS] = 177). Differences in 52-week efficacy outcomes between bimekizumab and secukinumab 300 mg dose escalation were non-significant (ESS = 120). Bimekizumab versus ixekizumab 80 mg comparisons (COAST-V only; ESS = 84) also suggested that differences were non-significant for most key efficacy outcomes. Other ixekizumab comparisons (COAST-V/-W; ESS = 45) suggested bimekizumab may have higher comparative efficacy for many of the same efficacy outcomes, however ixekizumab analyses were limited by poor population overlap, likely due to the greater proportion of patients with previous TNFi exposure. Conclusions: Patients treated with bimekizumab may have a higher likelihood of achieving improved longer-term efficacy versus secukinumab 150 mg, suggesting bimekizumab may be a favorable therapeutic option for r-axSpA. Differences in efficacy outcomes with bimekizumab versus ixekizumab 80 mg were mostly non-significant, depending on the populations considered.
| Item Type: | Article |
|---|---|
| Additional Information: | Data Availability statement: Data from the bimekizumab clinical trial used in this analysis may be requested by qualified researchers 6 months after product approval in the US and/or Europe, or if global development is discontinued, and 18 months after trial completion. Investigators may request access to anonymized individual patient data and redacted study documents which may include: raw datasets, analysis-ready datasets, study protocol, blank case report form, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to the use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data-sharing agreement will need to be executed. All documents are available in English only, for a pre-specified time, typically 12 months, on a password-protected portal. Funding information: This study and the journal’s Rapid Service Fee were funded by UCB Pharma. This article was based on published trials, including one that was sponsored by UCB Pharma. Support for third-party writing assistance for this article, provided by Evelyn Turner, BSc and James Evry, MSc, Costello Medical, Cambridge, UK, was funded by UCB Pharma in accordance with Good Publication Practice (GPP 2022) guidelines (https://www.ismpp.org/gpp-2022). |
| Uncontrolled Keywords: | axial spondyloarthritis,bdmards,bimekizumab,biologics,il-17 inhibitors,indirect comparison,ixekizumab,matching-adjusted indirect comparison,radiographic axial spondyloarthritis,secukinumab,rheumatology,immunology and allergy ,/dk/atira/pure/subjectarea/asjc/2700/2745 |
| Faculty \ School: | Faculty of Medicine and Health Sciences > Norwich Medical School |
| Related URLs: | |
| Depositing User: | LivePure Connector |
| Date Deposited: | 02 Sep 2024 09:30 |
| Last Modified: | 25 Sep 2024 18:04 |
| URI: | https://ueaeprints.uea.ac.uk/id/eprint/96410 |
| DOI: | 10.1007/s40744-024-00684-z |
Downloads
Downloads per month over past year
Actions (login required)
 |
View Item |